| Hormone Replacement Therapy (HRT) | |
Prempro Lawyers Blog Home Archives Prempro Breast Cancer Join Now! Prempro Class Action Lawsuits Learn about Breast Cancer and Ovarian Cancer cases
|
Prempro Lawyers : Blog Home : May 2005
A Philadelphia judge refused last week to certify a proposed statewide class action in which women taking the hormone-replacement drug Prempro were seeking medical monitoring.
The Phildelphia judge, Mark I. Bernstein, refused last week to certify a proposed statewide class action in which women were seeking medical monitoring, linking an increased risk of developing breast cancer to the hormone-replacement drug Prempro.
Wyeth argued that patients who use Prempro do not need any special monitoring because they are of post-menopausal age -- the age at which doctors already recommend that women undergo a mammogram once a year to screen for cancer.
Texas court rejects Prempro Class Action.May 5, 2005 07:39 JUDGE Rejects Class Action for Monitoring of Prempro Users Texas Lawyer (subscription) - TX,USA ... class action in which women were seeking medical monitoring, linking an increased risk of developing breast cancer to the hormone-replacement drug Prempro. ... <>
New Data Show Most Postmenopausal Women in Study Who Initiated Therapy With Wyeth's Low Dose Hormone Therapies Achieved Increased Bone Mineral DensityMay 13, 2005 07:43
The Women's HOPE Study evaluated four low dose options: Premarin 0.3 mg, PREMARIN 0.45 mg, Prempro 0.3 mg/1.5 mg, and PREMPRO 0.45 mg/1.5 mg. The newly published data can be accessed on the Web site for Osteoporosis International, the journal of the International Osteoporosis Foundation.
According to Robert Lindsay, MD, PhD, the lead author of this new report and Director, Clinical Research Center, Helen Hayes Hospital, these data add important new information about bone protection with low doses of PREMARIN or PREMPRO. At 24 months, women taking low doses of either PREMARIN or PREMPRO showed significant gains in spine BMD compared with women taking placebo. The percentages of women with an increase in spine BMD on low dose therapy ranged from 63.2% to 79.1% compared with 17.7% for placebo. By dose, the percentages were 63.2% for PREMARIN 0.3, 67.8% for PREMPRO 0.3/1.5, 74.2% for PREMPRO 0.45/1.5, and 79.1% for PREMARIN 0.45. The percentage of women taking PREMARIN 0.625 and PREMPRO 0.625/2.5 who experienced increases in spine BMD were 81.9% and 87.7%, respectively.
Panel cites 'information gap' on relieving menopauseMay 15, 2005 08:15
On March 24, 2005, After listening to 10 days' worth of presentations about treatments for hot flashes and other menopausal symptoms, an independent panel of scientists concluded Wednesday that there is insufficient evidence to wholeheartedly endorse any of them. This NIH State-of-the-Science panel supports use of hormone therapy for treatment of moderate to severe menopausal symptoms. A panel meeting in conjunction with this week's Conference on the Management of Menopause-Related Symptoms, convened by the National Institutes of Health (NIH), has issued a statement supporting the use of postmenopausal hormone therapy (HT) for the management of moderate to severe menopausal symptoms, such as hot flashes, night sweats, and...
Wyeth Pharmaceuticals (WYE) said according to a study, women taking low doses of either Premarin or Prempro, menopause drugs, showed "significant" gains in spine bone mineral density as compared to women taking placebos. Newly published data from the Women's Health, Osteoporosis, Progestin, and Estrogen (HOPE) Study now provide specific information about the percentages of individual postmenopausal women who experienced gains in bone mineral density (BMD) at the spine and the hip when taking low doses of PREMARIN(R) (conjugated estrogens tablets, USP) or PREMPRO for the relief of moderate to severe menopausal symptoms.
HRT May Help Heart, Swedish Research SuggestsMay 18, 2005 08:15
HealthCentral.com, Thu, 19 May 2005 1:05 AM PDT
WEDNESDAY, May 18 (HealthDay News) --
In findings that seem to contradict major U.S. research, heart specialists in Sweden report that hormone replacement therapy (HRT) may help improve cardiac function in postmenopausal women. A Small study finds it reduces enlarged cardiac muscle, but experts say that's not enough to end cautions. A small study found that a combination of estrogen and a progestin shrank dangerously enlarged heart muscle, acting much like the ACE inhibitor drugs doctors commonly prescribe for the condition.
300,000 women could sue Wyeth over PremproMay 22, 2005 08:15 On March 8, 2005 a Florida judge said that as many as 300,000 women could sue Wyeth as a group over claims that they were injured by Wyeth's Prempro hormone replacement therapy. The Florida judge said that as many as 300,000 women could sue Wyeth as a group over claims that they were injured by Wyeth's Prempro hormone-replacement therapy. The pharmaceutical company has operations in the Philadelphia area. Judge Lawrence Schwartz in Miami ruled last month that the women may band together in the lawsuit that seeks to receive court-supervised medical monitoring for future
HRT May Help Heart, Swedish Research SuggestsMay 22, 2005 08:15 WEDNESDAY, May 18 (HealthDay News) -- In findings that seem to contradict major U.S. research, heart specialists in Sweden report that hormone replacement therapy (HRT) may help improve cardiac function in postmenopausal women. http://www.healthcentral.com/newsdetail/408/525794.html
Metastatic neoplasm derived from placental tissueMay 23, 2005 08:15 Metastatic Choriocarcinoma to the Pancreas Gestational choriocarcinoma is a highly metastatic neoplasm derived from placental tissue, occurring in approximately 1:20,000- 40,000 pregnancies. Although gestational choriocarcinoma may follow any gestational event, it most commonly follows molar pregnancies.
Lawsuit Filed By Baltimore Woman Blaming Cancer on Hormone DrugsMay 26, 2005 08:15 A Baltimore woman has filed a multimillion-dollar lawsuit against half a dozen pharmaceutical companies, claiming she developed breast cancer as a result of taking Prempro and other hormone replacement therapy drugs. The suit, filed last week in federal district court in Baltimore by Sarah Jones, seeks $30 million in damages on seven counts including negligence, products liability, breach of warranty and fraud. http://www.rednova.com/news/display/?id=151998&source=r_health
HRT warning on cancer check May 27, 2005 15:52 Herald Sun, Wed, 25 May 2005 5:00 PM PDT WOMEN on hormone replacement therapy could get misleading results from breast cancer tests, Melbourne researchers have warned. Women on HRT who received negative results from their mammograms could still have cancer, a University of Melbourne study has found. Of more than 1500 Victorian women studied, mammograms found cancer in just 66 per cent of those on HRT -- compared with 83 per cent of women not taking HRT. All of the women in the five-year study had breast cancer.
Carcinoma Of The Breast (Breast Cancer)May 28, 2005 16:24 by Wong Lai Teng Currently, there are more than 180,000 new cases of breast cancer every year in the United States and 46,000 deaths, and it has been estimated that one of every eight American women living to age 95 years will develop breast carcinoma. Until 1983, breast cancer was the leading cause of cancer deaths among females; despite an increase in the incidence of breast carcinoma, it is now second to lung cancer because of the larger increase in the number of women developing lung cancer. About the Author www.medical-explorer.com
PremarinMay 30, 2005 13:17 Premarin stands for Pregnant Mares' Urine (PREgnant MARes' urINe); PMU for short (we spell it both ways, with an "e", PREgnant MARes' urINE which is the older name used in Canada, and without -- which is the more popular recent spelling, and the one that is a U.S. registered trademark).
Breast Cancer: Causes: PremproMay 30, 2005 16:16
Breast cancer is the most common type of cancer among women in this country (other than skin cancer). The number of new cases of breast cancer in women was estimated to be about 212,600 in 2003.
This National Cancer Institute (NCI) booklet (NIH Publication Number is 03-1556) has important information about breast cancer. It discusses possible causes, screening, symptoms, diagnosis, treatment, and recovery. It also has information to help women with breast cancer cope with the disease.
The biggest problem with Prempro are the dangerous side effects of long term use - Breast Cancer and Ovarian Cancer.
Medications: menopausal and pre-menopausal symptomsMay 31, 2005 16:24 PharmaBiz, Mon, 30 May 2005 7:45 PM PDT Win Medicare inks marketing deal with Orion Pharma for Divigel. The third of its kind in the recent times, the New Delhi-based Win Medicare (P) Ltd has signed another marketing tie-up with a foreign drug manufacturer. The latest agreement is with Orion Pharma for marketing Divigel, its medication for the treatment of menopausal and pre-menopausal symptoms.
|
Law Offices of Michael Monheit 1368 Barrowdale Road Rydal, PA 19046
Call Us Toll Free: 866-761-1385 P: 215-840-6573 E: Michael@Monheit.com
